Lawyers and Settlements
Home Page >> Potential Lawsuit >> Actemra Lawsuit

Actemra Linked to Heart Attacks and Deaths


Santa Clara, CA: A new drug used to treat rheumatoid arthritis (RA), Actemra (tocilizumab), which is made by Roche/Genentech, has been linked to hundreds of patient deaths resulting from heart attacks, strokes, and heart failure.

An investigation conducted by Stat News has shown that Actemra carried no warning labels concerning potential side effects, specifically cardiovascular and pulmonary complications. The investigation, which involved analysing more than 500,000 side effect reports on rheumatoid arthritis drugs, "found clear evidence" that the risk of the side effects such as heart attack or stroke, "were as high or higher for Actemra patients than for patients taking some competing drugs." The difference, according to Stat News, is that unlike other drug used to treat RA, Actemra does not carry a warning label for those side effects.

The Food and Drug Administration has received reports on 1,128 people who died after taking Actemra, and has reviewed its safety several times since it was approved.

Actemra is a humanized interleukin-6 (IL-6) receptor antagonist approved for treatment of adults with moderately to severely active rheumatoid arthritis. It was approved in 2010 and has been prescribed to more than 760,000 patients.



Actemra Legal Help

If you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on

DANGEROUS DRUGS LEGAL ARTICLES AND INTERVIEWS

Actemra Linked to Heart Attacks and Deaths, But Label Remains Unchanged
Actemra Linked to Heart Attacks and Deaths, But Label Remains Unchanged
November 20, 2017
Washington, DC: A recent presentation at the 2017 Annual Meeting of the American College of Rheumatology identified various factors that might predict the capacity for a patient suffering from rheumatoid arthritis (RA) to have success in tapering dosage of biologic medication such as Actemra (tocilizumab). The presentation was based on a study conducted by Dr. Takaaki Komiya and colleagues from Yokohama City University Graduate School of Medicine. However, according to WebMD (11/06/17), there was no mention of Actemra linked to heart attacks and deaths [READ MORE]

Time Runs Short for Actemra Lawsuits
Time Runs Short for Actemra Lawsuits
November 7, 2017
Washington, DC How is this possible when few, if any, Actemra lawsuits have even been filed yet? The answer lies in the tried-and-true defense pharmaceutical companies, like Roche and its subsidiary Genentech, will reach for first: the statute of limitations. The best thing a potential plaintiff can do is to file a lawsuit as soon as possible. Don’t wait [READ MORE]

Attorneys Investigating Actemra Complaints and its Approval Process
Attorneys Investigating Actemra Complaints and its Approval Process
October 31, 2017
Santa Clara, CA: On the heels of a STAT investigation that linked the rheumatoid arthritis drug Actemra to a number of deaths and many serious complications not listed on its label, attorneys are investigating potential lawsuits against Roche-Genentech, the manufacturer [READ MORE]



ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.